Anti-Infective - Page 1

Lightlake, NIDA collaborate to develop opioid addiction treatment
Friday, April 26, 2013 Lightlake Therapeutics has collaborated with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA), part of the US the National Institute on Drug Abuse (NIDA),...

Merck signs deal with Bristol-Myers for Phase II Hepatitis C trial
Wednesday, April 24, 2013 Merck has signed a non-exclusive agreement with Bristol-Myers Squibb to carry out a Phase II trial evaluating combined investigational oral candidates MK-5172 and Daclatasvir to treat...

Romark commences patient enrolment in Phase III trial of NT-300 influenza drug
Monday, April 22, 2013 Biopharmaceutical company Romark Laboratories has commenced patient enrolment in a Phase III trial of new influenza drug NT-300...

Vertex, Bristol-Myers sign deal to conduct Phase II hepatitis C all-oral studies
Tuesday, April 09, 2013 Vertex Pharmaceuticals has signed a non-exclusive agreement with Bristol-Myers Squibb Company to carry out Phase II all-oral studies of VX-135 in combination with daclatasvir for the treatment...

Trius tedizolid meets endpoints in Phase III ABSSSI study
Tuesday, March 26, 2013 Trius Therapeutics tedizolid phosphate (TR-701) has met all primary and secondary efficacy outcomes designated by the FDA and EMA in a Phase III study conducted in patients with severe...

Affinium reports positive results from Phase IIa study of AFN-1252
Friday, March 22, 2013 Affinium Pharmaceuticals has reported positive results from a Phase IIa study evaluating oral AFN-1252 in acute bacterial skin and skin structure infections...

Sinovac reports positive preliminary top-line data from EV71 Phase III trial
Friday, March 15, 2013 China-based Sinovac Biotech has reported preliminary top-line data from a Phase III trial evaluating Enterovirus 71 (EV71) vaccine against hand, foot and mouth disease (HFMD) in infants aged...

Sosei commences Phase III oropharyngeal candidiasis study of SO-1105
Wednesday, March 13, 2013 Japanese subsidiary of the Sosei Group, Sosei Co, has commenced Phase III study of an antifungal agent, SO-1105, for the treatment of oropharyngeal candidiasis caused by Candida...

Agenus completes patient enrolment in HSV-2 therapeutic vaccine study
Friday, March 01, 2013 Biotechnology company Agenus has finished enrolling patients in a double-blind, multicentre, randomised Phase II study of its recombinant therapeutic vaccine for the treatment of genital herpes...

Adynxx enrols first patient in investigational AYX1 Phase II study
Tuesday, February 26, 2013 Clinical-stage pharmaceutical company Adynxx has enrolled the first patient in a placebo-controlled Phase II clinical study of its lead investigational drug candidate,...

Immune commences ulcerative colitis drug Phase II study
Friday, February 22, 2013 Israel-based Immune Pharmaceuticals has commenced a double-blind, parallel group, randomised and placebo-controlled Phase II study of bertilimumab for the treatment of moderate-to-severe...

Regeneron, Bayer commence Phase III trial of Eylea injection
Thursday, February 21, 2013 Regeneron Pharmaceuticals and Bayer HealthCare have commenced a new Phase III trial of their Eylea (aflibercept) injection for the treatment of diabetic macular edema (DME) in Russia, China,...

Gilead reports positive results from two Phase III hepatitis C virus studies
Wednesday, February 06, 2013 Gilead Sciences has reported positive topline results from two Phase III studies, FISSION and NEUTRINO, of sofosbuvir conducted in patients infected with hepatitis C virus (HCV) and who were new...

Anacor reports positive preliminary results from tavaborole Phase III onychomycosis trial
Thursday, January 31, 2013 Biopharmaceutical company Anacor Pharmaceuticals has reported positive preliminary results from the first of two Phase III trials of topical anti-fungal tavaborole, designed to treat...

Idenix, Janssen collaborate to develop HCV combination therapies
Wednesday, January 30, 2013 Idenix Pharmaceuticals has entered into a non-exclusive collaboration with Janssen Pharmaceuticals to commence Phase II all-oral combination studies evaluating IDX719, simeprevir (TMC435)...

IBM, The Institute of Bioengineering and Nanotechnology jointly develop antimicrobial hydrogel
Monday, January 28, 2013 IBM and The Institute of Bioengineering and Nanotechnology have developed a new biodegradable, biocompatible antimicrobial hydrogel that ruptures diseased biofilms and eliminates...

Gilead commences Phase III study of tenofovir alafenamide to treat HIV
Friday, January 25, 2013 Gilead Sciences has commenced a Phase III trial (Study 104) of tenofovir alafenamide (TAF), a nucleotide reverse transcriptase inhibitor for the treatment of...

Emergent initiates Phase II BioThrax study to support post-exposure prophylaxis indication
Wednesday, January 23, 2013 Specialty pharmaceutical company Emergent Biosolutions has initiated a non-interference Phase II study of BioThrax (anthrax vaccine adsorbed) to treat exposure to anthrax spores....

Emergent commences dosing in Phase 2 trial of NuThrax anthrax vaccine
Friday, January 18, 2013 Specialty pharmaceutical company Emergent BioSolutions has dosed the first subject in the Phase 2 trial evaluating anthrax vaccine NuThrax that is adsorbed in combination with CPG...

FDA approves Janssen pulmonary multi-drug resistant tuberculosis therapy
Wednesday, January 02, 2013 Janssen Therapeutics, Division of Janssen Products, has received accelerated approval for Sirturo (bedaquiline) tablets from the US FDA to treat adult pulmonary multi-drug resistant...